Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Kapil Saxena"'
Autor:
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, DESTINY-CRC01 investigators
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prio
Externí odkaz:
https://doaj.org/article/b78d3fdfa83149b6a91ce6f79897ff81
Autor:
Nuria Garcia, Rufus Mitchell-Heggs, Kapil Saxena, Sumantra Chattarji, Peter Kind, Simon Schultz, Richard Morris
Publikováno v:
IBRO Neuroscience Reports, Vol 15, Iss , Pp S92- (2023)
Externí odkaz:
https://doaj.org/article/29e14cfded004d538d26f664b51d02c4
Autor:
Claire Roddie, Karamjeet Sandhu, Eleni Tholouli, Paul Shaughnessy, Pere Barba Suñol, Manuel Nuno Direito de Morais Guerreiro, Mehrdad Abedi, Michael Bishop, Jean Yared, Armin Ghobadi, Deborah Yallop, Aaron Logan, Beitinjaneh Amer, Jeremy Pantin, Martha L Arellano, Sridhar Chaganti, Ram Malladi, Tobias Menne, Virginia Escamilla, Katharine Hodby, Krishna Gundabolu, Luke Mountjoy, Kristen Odwyer, Sameem Abedin, Hassan Alkhateeb, Bijal Shah, Silvia Basilico, Deborah Cluxton, Joanna Dawes, Pierre Lao-Sirieix, Meera Raymond, Justin Shang, Yanqing Hu, Gianfranco Pittari, Kapil Saxena, Wolfram Brugger, Y Zhang, Martin Pule, Daniel Park, Daniel De Angelo, Elias Jabbour
Publikováno v:
HemaSphere, Vol 7, p e998506d (2023)
Externí odkaz:
https://doaj.org/article/847828f94a674a0c9263a5a47141ff67
Publikováno v:
Frontiers in Materials, Vol 9 (2022)
In the present study, the controllable fabrication of silicon nanowires (Si NWs) with vertical alignment was accomplished using metal assisted chemical etching (MACE). The different characteristics, such as structural, morphological, chemical, optica
Externí odkaz:
https://doaj.org/article/f5c77544e7e8448b8e8bccd4ba876420
Autor:
Kapil Saxena, Elias Jabbour, Ghayas Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti, Naval Daver, Tapan Kadia, Courtney D. DiNardo, Marina Konopleva, Jorge E. Cortes, Musa Yilmaz, Kelly Chien, Sherry Pierce, Hagop Kantarjian, Nicholas J. Short
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Abstract Background The natural course of untreated chronic myeloid leukemia (CML) is progression to an aggressive blast phase. Even in the current era of BCR-ABL1 tyrosine kinase inhibitors (TKIs), the outcomes of blast phase CML remain poor with no
Externí odkaz:
https://doaj.org/article/18fdadb2cd3742fba049aac9f04afa0a
Publikováno v:
Silicon. 15:1203-1210
Autor:
Daniel Surinach, Mathew L Rynes, Kapil Saxena, Eunsong Ko, A David Redish, Suhasa B Kodandaramaiah
Publikováno v:
bioRxiv
Spatial navigation is a complex cognitive process that involves neural computations in distributed regions of the brain. Little is known about how cortical regions are coordinated when animals navigate novel spatial environments or how that coordinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dc53ea7b8e434f55641f067c6b482b6
https://europepmc.org/articles/PMC10081171/
https://europepmc.org/articles/PMC10081171/
Autor:
Marina Konopleva, Courtney DiNardo, Tushar Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena, Tianyu Cai, Xiaoping Su, Anna Skwarska, Veronica Guerra, Vinitha Kuruvilla, Sergej Konoplev, Shanisha Gordon-Mitchell, Kith Pradhan, Srinivas Aluri, Meghan Collins, Shannon Sweeney, Jonathan Busquet, Atul Rathore, Qing Deng, Michael Green, Steven Grant, Susan Demo, Gaurav Choudhary, Srabani Sahu, Beamon Agarwal, Mason Spodek, Victor Thiruthuvanathan, Britta Will, Ulrich Steidl, George Tippett, Jan Burger, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Tapan Kadia, Steven Kornblau, Naval Daver, Kiran Naqvi, Nicholas Short, Guillermo Garcia-Manero, Stefano Tiziani, Amit Verma
Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d49b9bc46598eb8d2130f229c871d80
https://doi.org/10.21203/rs.3.rs-2518774/v1
https://doi.org/10.21203/rs.3.rs-2518774/v1
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:133-139
The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with speci
Autor:
Julien Mazieres, Patrik Vitazka, Lyudmila Bazhenova, Pasi A. Jänne, Misako Nagasaka, DESTINY-Lung Trial Investigators, Enriqueta Felip, Luis Paz-Ares, Ryota Shiga, Yingkai Cheng, Yasushi Goto, Kapil Saxena, Kazuhiko Nakagawa, Maurice Pérol, Javad Shahidi, Jose M. Pacheco, Bob T. Li, David Planchard, Hibiki Udagawa, Egbert F. Smit, Suddhasatta Acharyya, Andreas Saltos
Publikováno v:
DESTINY-Lung01 Trial Investigators 2022, ' Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer ', New England Journal of Medicine, vol. 386, no. 3, pp. 241-251 . https://doi.org/10.1056/NEJMoa2112431
N Engl J Med
New England Journal of Medicine. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
The New England journal of medicine, vol 386, iss 3
New England Journal of Medicine, 386(3), 241-251. Massachussetts Medical Society
N Engl J Med
New England Journal of Medicine. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine
The New England journal of medicine, vol 386, iss 3
New England Journal of Medicine, 386(3), 241-251. Massachussetts Medical Society
Background Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conj